Showing the latest 10 filings. Sign in to filter or browse the full history.
Showing 10 of 78 filings.
12 Oct 20261 filing
No brief for this announcement.This type of announcement aren’t summarised. View the original using the link below
2 Oct 20262 filings
No brief for this announcement.Newspaper publications aren’t summarised. View the original using the link below
No brief for this announcement.Newspaper publications aren’t summarised. View the original using the link below
30 Sept 20262 filings
No brief for this announcement.Newspaper publications aren’t summarised. View the original using the link below
No brief for this announcement.Newspaper publications aren’t summarised. View the original using the link below
29 Sept 20261 filing
Governance & Board Changes
- Kirti Ganorkar appointed Managing Director from 01-Sep-2025; Dilip Shanghvi becomes Executive Chairman.
- Dr. Pawan Goenka appointed Lead Independent Director; Rama Bijapurkar retired May 20, 2026.
- Board size eight: four Executive, four Independent; independent Directors constitute 50%.
- Two female directors on the board; governance framework reinforced.
Climate & Environmental Targets
- Scope 1+2 emissions target: 35% reduction by 2030 vs 2020.
- FY2026 progress: 15.86% absolute reduction; 43% renewable energy; 16.05% water reduction; ZLD at 16 sites.
R&D & Innovation
- FY2026 R&D investment: INR 35.5 billion; 6.1% of revenue.
- Cumulative R&D spend: INR 335+ billion; 2,700+ R&D staff; 29 innovative medicines.
Ownership & Assurance
- Promoter group ownership 54.48%; LIC of India 5.23%.
- External ESG assurance by DNV VeriSustain Limited; limited assurance scope.
28 Sept 20263 filings
Postal ballot results
- Postal ballot completed 26 September 2026; resolution approved by requisite majority.
- Voting results submitted to stock exchanges.
- Scrutinizer's report available on Sun Pharma website.
Agreement highlights
- Exclusive worldwide rights outside US and China granted to Sun Pharma.
Regulatory status
- EU approval for lerodalcibep (Lyrokaul) received on Sep 21, 2026.
Commercial terms
- Upfront and milestone payments plus royalties on net sales in licensed territories.
Market context
- Global PCSK9 market outside US/China valued at US$3.7B in MAT Q2 2026.
- Market growth cited at 38% CAGR over prior two years.
Product and regulatory details
- Lerodalcibep approved in EU for hypercholesterolaemia and mixed dyslipidaemia.
- US FDA approval under brand Lerochol; autoinjector and PFS options.
- Dosing once-monthly 300 mg/1.2 mL subcutaneous.
- Six-month ambient storage permitted in EU label.
Deal highlights
- Exclusive global license for lerodalcibep outside the US and China.
- Sun Pharma to commercialize and manufacture Lerodalcibep in licensed territories.
- LIB receives upfront, milestones and royalties based on net sales.
- Rights exclude the United States and China; EU label storage updated.
- EU approval for Lyrokaul obtained Sept 21, 2026; six-month ambient storage.
- PCSK9 market outside US/China valued US$3.7B; 38% CAGR.
- EU market size supports future expansion of LDL-C therapies.
- Sun Pharma to pursue regulatory approvals where not yet obtained.
26 Sept 20261 filing
Shareholder reclassification
- Shareholders approved reclassification on 26 September 2026 from Promoter Group to Public under Regulation 31A.
- Effect to be reflected in subsequent quarterly shareholding patterns filed with stock exchanges.
- Compliance with SEBI Listing Regulations 2015, Regulation 31A.
- No change in management or promoter control; governance structure remains unchanged.
- Intimation filed under Regulation 30 and Regulation 31A for the reclassification.